Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 7/20 | 0.64 |
| ▸ | EHMT2 | Q96KQ7 | 13/20 | 0.64 |
| ▸ | KDM1A | O60341 | 1/20 | 0.60 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.60 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.58 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.58 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.58 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16521336 | 0.89 | EHMT2 (0.75) | NSD2EHMT2KDM1ARCOR1DNMT3A | |
| SCHEMBL15280229 | 0.88 | NSD2 (0.80) | NSD2EHMT2KDM1ARCOR1DNMT3A | |
| SCHEMBL15280473 | 0.87 | EHMT2 (0.82) | NSD2EHMT2KDM1ADNMT3AEZH2 | |
| SCHEMBL15280364 | 0.86 | EHMT2 (0.83) | NSD2EHMT2KDM1ADNMT3AEZH2 | |
| SCHEMBL1748578 | 0.84 | EHMT2 (0.62) | NSD2EHMT2KDM1ARCOR1 | |
| SCHEMBL1748362 | 0.83 | EHMT2 (0.60) | NSD2EHMT2KDM1ARCOR1DNMT3A | |
| SCHEMBL1748561 | 0.83 | EHMT2 (0.61) | NSD2EHMT2KDM1ARCOR1DNMT3A | |
| SCHEMBL15280265 | 0.83 | EHMT2 (0.77) | NSD2EHMT2KDM1ARCOR1DNMT3A | |
| SCHEMBL15280243 | 0.82 | EHMT2 (0.75) | NSD2EHMT2KDM1ARCOR1DNMT3A | |
| SCHEMBL1748467 | 0.82 | EHMT2 (0.62) | NSD2EHMT2KDM1ARCOR1DNMT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2828250-B1 | QUINAZOLINE COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2021-03-10 | — | — | EP | disclosed |
| US-9932317-B2 | Quinazoline compounds and their use in therapy | IMPERIAL INNOVATIONS LIMITED (GB) | 2018-04-03 | — | — | US | disclosed |
| US-20150057263-A1 | Quinazoline Compounds And Their Use In Therapy | IMPERIAL WHITE CITY INCUBATOR LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| WO-2013140148-A1 | QUINAZOLINE COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057263-A1 | Quinazoline Compounds And Their Use In Therapy | EZH2, EHMT1, HNMT | NSD2 119/4885EHMT2 4/4885KDM1A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.